American Society of Nephrology Kidney Week 2020

Finerenone reduces CKD progression, CV risk

Roshini Claire Anthony, 20201211180001

Treatment with the nonsteroidal, selective mineralocorticoid receptor antagonist finerenone reduced chronic kidney disease (CKD) progression and cardiovascular (CV) event risk in patients with CKD and type 2 diabetes (T2D), according to the FIDELIO-DKD* study presented at ASN Kidney Week 2020.

Evidence-based intervention fails to reduce haemodialysis catheter-related bloodstream infection

Roshini Claire Anthony, 20201201180001

An evidence-based, multifaceted intervention aimed at reducing haemodialysis catheter-related bloodstream infections (HD-CRBSIs) failed to improve this outcome, results of the REDUCCTION* trial showed.

Regional citrate trumps systemic heparin for extending dialysis filter lifespan

Regional citrate trumps systemic heparin for dialysis filter

Pearl Toh, 20201128141000

Using regional citrate for anticoagulation during dialysis significantly extends the lifespan of dialysis filter compared with systemic heparin anticoagulation, although this has no impact on the patients’ mortality rate over 1 year, according to the RICH study presented at ASN 2020.

Metformin may have CV benefits in CKD patients with MetS

Audrey Abella, 20201120100000

Metformin may improve vascular function in chronic kidney disease (CKD) patients with metabolic syndrome (MetS), according to a study presented at ASN Kidney Week 2020.

Glomerular disease tied to increased CVD risk

Roshini Claire Anthony, 20201117180001

Adults with glomerular disease have a more than twofold risk of cardiovascular (CV) events compared with the general population, with the risk varying by type of glomerular disease, according to a retrospective study presented at ASN Kidney Week 2020.

Icosapent ethyl shows consistent benefit in statin-treated patients regardless of eGFR status

Audrey Abella, 20201116100000

The REDUCE-IT* RENAL study, a substudy of the REDUCE-IT trial, reflected the consistent benefit of icosapent ethyl (IPE) in statin-treated patients with established** cardiovascular disease (CVD) or diabetes, regardless of eGFR*** status.

No excess CV risk with vadadustat in CKD patients not on dialysis

Pearl Toh, 20201114150000

Using vadadustat for treating anaemia in patients with chronic kidney disease (CKD) not on dialysis does not come with excess cardiovascular (CV) risk compared with darbepoetin alfa, particularly for those treated to a target Hb range of 10–11 g/dL, according to a prespecified analysis of the PRO2TECT study presented at ASN 2020 Kidney Week.

Upacicalcet may manage secondary hyperparathyroidism in dialysis patients

Audrey Abella, 20201113100000

The administration of upacicalcet – a novel, small-molecule calcimimetic agent in late-stage development in Japan – led to a significant reduction in serum intact parathyroid hormone (iPTH) level without increasing upper gastrointestinal (GI) symptoms in patients who have secondary hyperparathyroidism following haemodialysis, according to a phase III trial presented at ASN Kidney Week 2020.

More protein of no help for haemodialysis patients?

More protein of no help for dialysis patients?

Pearl Toh, 20201112140010

Adding nutritional supplements, particularly protein, to diet of patients undergoing haemodialysis does not give an edge in survival compared with standard nutritional supplements, according to the HELPS-HD* study.